Jérôme Hadjadj,Nader Yatim,Laura Barnabei,Aurélien Corneau,Jeremy Boussier,Nikaïa Smith,Hélène Péré,Bruno Charbit,Vincent Bondet,Camille Chenevier-Gobeaux,Paul Breillat,Nicolas Carlier,Rémy Gauzit,Caroline Morbieu,Frédéric Pène,Nathalie Marin,Nicolas Roche,Tali-Anne Szwebel,Sarah H Merkling,Jean-Marc Treluyer,David Veyer,Luc Mouthon,Catherine Blanc,Pierre-Louis Tharaux,Flore Rozenberg,Alain Fischer,Darragh Duffy,Frédéric Rieux-Laucat,Solen Kernéis,Benjamin Terrier,Sarah H. Merkling

Abstract:Interferons interfere with lung repair Interferons (IFNs) are central to antiviral immunity. Viral recognition elicits IFN production, which in turn triggers the transcription of IFN-stimulated genes (ISGs), which engage in various antiviral functions. Type I IFNs (IFN-α and IFN-β) are widely expressed and can result in immunopathology during viral infections. By contrast, type III IFN (IFN-λ) responses are primarily restricted to mucosal surfaces and are thought to confer antiviral protection without driving damaging proinflammatory responses. Accordingly, IFN-λ has been proposed as a therapeutic in coronavirus disease 2019 (COVID-19) and other such viral respiratory diseases (see the Perspective by Grajales-Reyes and Colonna). Broggi et al. report that COVID-19 patient morbidity correlates with the high expression of type I and III IFNs in the lung. Furthermore, IFN-λ secreted by dendritic cells in the lungs of mice exposed to synthetic viral RNA causes damage to the lung epithelium, which increases susceptibility to lethal bacterial superinfections. Similarly, using a mouse model of influenza infection, Major et al. found that IFN signaling (especially IFN-λ) hampers lung repair by inducing p53 and inhibiting epithelial proliferation and differentiation. Complicating this picture, Hadjadj et al. observed that peripheral blood immune cells from severe and critical COVID-19 patients have diminished type I IFN and enhanced proinflammatory interleukin-6– and tumor necrosis factor-α–fueled responses. This suggests that in contrast to local production, systemic production of IFNs may be beneficial. The results of this trio of studies suggest that the location, timing, and duration of IFN exposure are critical parameters underlying the success or failure of therapeutics for viral respiratory infections. Science , this issue p. 706 , p. 712 , p. 718 ; see also p. 626

The type I interferon response in COVID-19: implications for treatment

Type I Interferons in the Pathogenesis and Treatment of Sjögren’s Syndrome: an Update

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

The role of type I interferon in the treatment of COVID‐19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond

Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

Dysregulation of type I interferon responses in COVID-19

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Serum Levels of Type I Interferon (IFN-I) is Associated with the Severity of COVID-19.

Type I interferon pathway genetic variants in severe COVID-19

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

Protective versus Pathogenic Type I Interferon Responses during Virus Infections

Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity

Interferon-I modulation and natural products: Unraveling mechanisms and therapeutic potential in severe COVID-19

Specialized interferon action in COVID-19

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions